1. Scrip
  2. >>Business
  3. >>Deals

Patient-Centric: Evotec’s CSO Explains R&D Strategy

Says Patient-Driven Data Is Key For Precision Medicine

 
• By Sten Stovall

Evotec’s multimodality approach to drug discovery landed the biotech two new discovery collaborations this week, underscoring its emphasis on patient-driven data.

Patient_Data
Its two latest R&D alliances underline Evotec’s data-focused strategy. • Source: Shutterstock

Evotec SE has again stressed its view that patient-driven data are the future for innovation, most recently by inking an R&D pact with Centogene in Gaucher’s disease, two days after the German drug discovery and development company entered a new alliance with Novo Nordisk A/S in chronic kidney disease. Its chief science officer Cord Dohrmann told Scrip that more, similarly structured collaborations can be expected.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

Zepbound Grows, But CVS/Novo Nordisk Deal For Wegovy Casts Shadow

 
• By Alaric DeArment

Lilly executives told the company’s Q1 call they were not surprised at the Wegovy deal, but some analysts said it could cut into prescription growth for Zepbound.

Scrip M&A Podcast: Will FDA Staff Cuts Impact Biopharma Dealmaking?

 
• By Joseph Haas

Attorneys Andrew Goodman and Alan Minsk, as well as Naya CEO Daniel Teper, discussed the ramifications of US FDA staff cuts on M&A activity with Scrip senior writer Joseph Haas.

GSK Talks Up Nucala COPD Hospitalization Data In Challenge To Dupixent

 
• By Kevin Grogan

As the PDUFA date for the UK major’s IL-5 inhibitor draws close.